% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, AŞ Message Board

  • johnpapas893 johnpapas893 Dec 11, 2012 1:56 PM Flag


    How do these results compare to Carfilzomib?

    Celgene laid out its case for its multiple myeloma blockbuster hopeful pomalidomide at the American Society of Hematology meeting, boasting of an improved promise of overall survival, progression-free survival and overall response rate among a group of very sick patients who had failed either Revlimid or Velcade.

    Patients on a regimen of pomalidomide and low-dose dexamethasone achieved a median PFS rate of 3.6 months compared with 1.8 months in a high-dose dexamethasone arm. There was also a "highly statistically significant improvement in overall survival that crossed the upper boundary for superiority," prompting the safety monitoring committee to cross over the control arm into the pomalidomide group. And the overall response rate hit 21% compared with 3% in the control arm.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies